Navigation Links
Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
Date:5/16/2013

QUEBEC CITY, May 16, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company will present four posters at the 2013 American Thoracic Society (ATS) International Conference, taking place May 17-22 in Philadelphia. All four will describe data around ASM-024, Asmacure's lead development compound, currently in development for asthma and chronic obstructive pulmonary disease.

Following are details for each embargoed session (all Eastern Daylight Time):

Sunday, May 19:

  • Smooth Muscle Relaxant Profile Of ASM-024, A New Compound With Dual Nicotinic And Muscarinic Activity- Comparison With Muscarinic Antagonists (Poster #F76)
    Lead author: Evelyne Israel-Assayag , M.Sc., Asmacure
    Poster session A43 – COPD Treatment: Novel Agents and Safety Studies (Halls C-D)
    8:15 a.m. – 4:30 p.m.

    Exploration Of The Mechanism Underlying The Relaxation Response Induced By ASM-024 On Guinea-pig Tracheas (Poster #507)
    Lead author: Marie-Josee Beaulieu , M.Sc., Universite, Quebec, Qc , Canada
    Poster Discussion Session A108 – Airway Smooth Muscle: New Ways to Relax and Behave (Room 201C)
    2 p.m. – 4 p.m.

Monday, May 20:

  • Effects Of ASM-024, A New Compound With Dual Nicotinic And Muscarinic Activity, On Airway Responsiveness And Allergen-Induced Responses In Mild Asthmatics (Poster #B25)
    Lead author: Louis-Philippe Boulet , M.D., Universite Laval, Quebec, Qc, Canada
    Poster session B32 – Advances in Asthma Therapy (Halls C-D)
    8:15 a.m. – 4:30 p.m.
  • Relaxant Effects Of ASM-024, A New Compound With Dual Nicotinic And Muscarinic Activity, On b 2-Agonist Desensitized Guinea-Pig Tracheas (Poster #B41)
    Lead author: Yvon Cormier , M.D., Asmacure and Universite Laval
    Poster session B32 – Advances in Asthma Therapy (Halls C-D)
    8:15 a.m.-4:30 p.m.

About Asthma
Asthma is a reversible obstructive lung disease, caused by increased reaction of the airways to various stimuli. It is a chronic inflammatory condition with acute exacerbations. Asthma can be a life-threatening disease if not properly managed. According to the American Lung Association in 2011 it was estimated that 25.9 million Americans currently have asthma, including 7.1 million children under 18. Of these, 13.2 million Americans (4.1 million children) had an asthma attack. Close to 2.1 million emergency room visits were attributed to asthma in 2009.

About ASM-024
The company's lead development compound, ASM-024, with its novel mechanism of action, has demonstrated the capabilities of inhibitory effects on inflammation, bronchoprotection and smooth muscle relaxation in pre-clinical asthma models. ASM-024 delivered as a solution for nebulization achieved proof of concept in the treatment of patients with asthma in a phase 2 clinical trial program. The company is now focused on bridging from the ASM-024 solution formulation to the development of the compound in a dry powder for inhalation (DPI) dosage form. Typically, DPI's are a preferred dosage form for pulmonary products by allowing for delivery of lower, more optimal dosing with greater lung deposition.

ASM-024 demonstrated a highly-significant effect on FEV₁ and methacholine PC₂₀ pre-allergen challenge in a phase 2 study utilizing the solution for nebulization formulation. In pre-clinical asthma models, ASM-024 has demonstrated an adjunctive benefit when combined with long- and short-acting ß-agonists and long- and short-acting muscarinic antagonists.

Based on recent findings about the novel mechanism of action for ASM-024 with nicotinic and muscarinic effects, Asmacure will initiate a phase 2 study in COPD patients in the third quarter of this year.

About Asmacure
Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases. The company's lead compound, ASM-024, has a novel mechanism with multi-functional properties at the nicotinic and muscarinic levels. Asmacure was founded by Dr. Yvon Cormier , a noted pulmonologist, and Evelyne Israel-Assayag in 2002 and is based in Quebec City, (Quebec) Canada. Asmacure is a privately-held company with the major investors including Domain Associates, Fonds de solidarite des travailleurs du Quebec (F.T.Q.) and Desjardins-Innovatech s.e.c. For more information visit www.asmacure.com.

Contact:
E. Blair Schoeb
Tel: 917-432-9275
blair@biotechcomm.com

 


'/>"/>
SOURCE Asmacure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asmacure Dosed First Subjects With ASM-024 Dry Powder For Inhalation
2. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
3. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
4. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
5. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
6. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
7. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
8. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
9. Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
10. AMRI CFO to Present at the UBS Global Healthcare Conference
11. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. ... saving and improving the lives of pets, today announced ... of the New Animal Drug Application (NADA) for Zimeta™ ... field study (KB0120) of Zimeta for the control of ... Company. --> --> ...
(Date:2/11/2016)... 2016   Health 2.0 , the premiere showcase ... announced today " 10 Year Global Retrospective ", a ... the past ten years.   --> ... 2.0 has served as the preeminent thought-leader in the ... of technologies, companies, innovators, and patient-activists through an array ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... Sun City is the place to be on March 3rd to learn about the latest ... hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting advancements will be presented ... addition, prizes will be given away and light refreshments will be served. , As ...
(Date:2/13/2016)... ... ... Many individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and increased ... has delved into this niche allowing those giving up their beloved pasta a chance ... grams of protein and only 7 grams of carbohydrates per 50 gram serving--a ratio ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly released ... visualization technology should be used to ensure patient safety when placing an IV ... Standards mandate the use of vein visualization technology in patients with difficult venous ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or ... groom themselves to perfection, go out of their way to be romantic, and may ... take a look at any online dating profile. , A recent study from ...
(Date:2/12/2016)... San Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... of love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. ... in fact a love story, the love of a Buddhist teacher for teaching and ...
Breaking Medicine News(10 mins):